Fenofibrate¹¹ Fenofibrate
a fibric acid derivative drug prescribed to lower triglycerides, raise HDL, and reduce cardiovascular risk in people with atherogenic dyslipidemia has always been puzzling: large trials like ACCORD-Lipid showed that adding fenofibrate to statin therapy produces no average cardiovascular benefit. But "no average benefit" conceals a striking pharmacogenomic split. A variant at rs6008845 — a regulatory site near the PPARA gene on chromosome 22 — predicts with unusual precision which patients get a dramatic 51% reduction in heart attacks and strokes, and which get nothing at all.

The Mechanism

PPARA²² PPARA
Peroxisome Proliferator-Activated Receptor Alpha, a nuclear receptor that acts as a master switch for fatty acid oxidation, triglyceride clearance, and anti-inflammatory gene regulation in the liver, vascular wall, and heart is the direct molecular target of fenofibrate. When fenofibrate binds and activates PPARα, the receptor promotes fatty acid catabolism, lowers triglycerides and raises HDL, and simultaneously suppresses pro-inflammatory transcription factors (NF-κB, AP-1) through a process called transrepression — a mechanism directly relevant to plaque stabilization.

rs6008845 sits approximately 21 kb upstream of the PPARA transcription start site. dbSNP annotates it against a nearby uncharacterized transcript (LOC124905137), but GTEx eQTL analysis³³ GTEx eQTL analysis
expression quantitative trait locus data from hundreds of post-mortem tissue samples shows that rs6008845 is a significant cis-regulatory variant for PPARA expression across multiple tissues. The T allele (the GRCh38 reference) is associated with higher or more appropriately-regulated PPARA expression; the C allele appears to reduce it. This makes TT carriers the group in whom fenofibrate most effectively amplifies an already-primed PPARα response — rather than trying to activate a receptor that is intrinsically under-expressed.

In a remarkable mechanistic finding, the ACCORD-Lipid pharmacogenomics study showed that in TT homozygotes specifically, fenofibrate significantly reduced circulating levels of CCL11 (eotaxin)⁴⁴ CCL11 (eotaxin)
a pro-inflammatory chemokine that recruits eosinophils and contributes to vascular inflammation and atherogenesis (P for interaction = 0.003). This effect was absent in C-allele carriers — suggesting that the TT genotype enables fenofibrate to activate a specific anti-inflammatory PPARα pathway that is blunted or absent when the C allele reduces PPARA expression.

The Evidence

The primary pharmacogenomic discovery comes from Morieri ML et al. 2020⁵⁵ Morieri ML et al. 2020
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes 69:771–783, a pre-specified pharmacogenomic analysis of the ACCORD-Lipid randomized controlled trial. The discovery cohort included 3,065 white patients with type 2 diabetes, all on background statin therapy, randomized to fenofibrate or placebo. TT homozygotes (36% of white participants) experienced a 51% reduction in MACE (major adverse cardiovascular events): hazard ratio 0.49 (95% CI 0.34–0.72). CT and CC carriers showed zero cardiovascular benefit. The genotype-by-treatment interaction p-value was 3.7 × 10⁻⁴, exceeding pre-specified study-wide significance. Critically, the TT benefit persisted even in patients without classical atherogenic dyslipidemia (low HDL, high triglycerides), suggesting a lipid-independent mechanism — likely the CCL11 anti-inflammatory pathway.

Replication in African Americans within ACCORD (N=585) confirmed the same direction (P=0.02). Three external cohorts (ACCORD-BP, ORIGIN, TRIUMPH; combined N=3,059) replicated the interaction (P=0.005). Total replication sample size: 6,709 participants across four independent populations.

A contrasting finding came from Januszewski et al. 2026⁶⁶ Januszewski et al. 2026
FIELD trial substudy. Diabetes Res Clin Pract 234:113168 analyzing 8,159 participants over five years. Here fenofibrate reduced microvascular and macrovascular events consistently regardless of rs6008845 genotype (HR 0.79–0.87, all P<0.02), with no treatment-by-genotype interaction. The FIELD trial also found that T-allele carriers had somewhat higher baseline microvascular risk (HR 1.15 for TT vs CC). The discordance between ACCORD-Lipid and FIELD may reflect differences in study design (background statin vs no statin), statistical power, or phenotype definitions. The ACCORD finding is the larger and more precisely powered pharmacogenomic analysis with prospectively defined endpoints.

Evidence level: strong — replicated in five independent cohorts with a mechanistic CCL11 pathway identified, but full clinical guideline incorporation has not yet occurred.

Practical Actions

For CC and CT carriers on statin therapy, the ACCORD-Lipid data suggest that adding fenofibrate to statin therapy for cardiovascular protection alone is unlikely to be beneficial. The established approach — statin therapy first, with fibrate considered if atherogenic dyslipidemia persists — remains appropriate, but the pharmacogenomic data sharpen expectations: fibrates may improve the lipid profile without translating to cardiovascular event reduction in C-allele carriers. Targeting triglycerides below 150 mg/dL and raising HDL through omega-3 supplementation and dietary fat optimization remains relevant regardless of genotype.

For TT carriers, the data support discussing fenofibrate eligibility with a prescriber specifically for cardiovascular protection — even without classic dyslipidemia — when type 2 diabetes is present. The CCL11/eotaxin mechanism suggests the benefit is partly anti-inflammatory, not purely lipid-mediated, so lipid panels alone do not capture the full pharmacogenomic benefit signal.

Interactions

rs6008845 should be interpreted alongside other PPARA functional variants. The coding variant rs1800206 (Leu162Val) directly alters PPARα's ligand-binding domain and affects both spontaneous cardiovascular risk and fibrate lipid response. The intronic variant rs4253623 associates with myocardial infarction risk in a single study. The intron 7 variant rs4253778 affects PPARα expression in cardiac and muscle tissue during exercise. None of these variants are in strong linkage disequilibrium with rs6008845, so they represent independent functional signals; a person may carry multiple PPARA variants with additive or independent effects on PPARα biology.

Omega-3 fatty acids (EPA and DHA) are direct PPARα ligands that activate the receptor regardless of rs6008845 genotype, and may partially compensate for any C-allele-mediated reduction in PPARA expression by providing supraphysiological receptor activation.

Fibrinogen¹¹ Fibrinogen
A 340 kDa plasma protein synthesized in the liver that circulates at 2–4 g/L. Thrombin cleaves fibrinogen to produce fibrin monomers that polymerize into the mesh scaffold of a blood clot is the final common substrate of coagulation. The FGA gene encodes the fibrinogen alpha chain, one of three polypeptide chains that assemble into the hexameric fibrinogen molecule. The Thr312Ala variant (rs6050) substitutes alanine for threonine at position 312 of the alpha chain — precisely within the alphaC domain, a region critical for lateral fibrin aggregation and for the cross-linking reactions that give a mature clot its tensile strength. Whether you carry this substitution shapes not just whether a clot forms, but how easily it can be dissolved once formed — a distinction with specific implications for pulmonary embolism risk.

The Mechanism

When thrombin cleaves fibrinogen, the resulting fibrin monomers polymerize end-to-end into protofibrils. These protofibrils then laterally aggregate — a process partly mediated by the alphaC domain²² alphaC domain
The C-terminal portion of the fibrinogen alpha chain, spanning residues ~220–610, that mediates lateral protofibril aggregation and Factor XIIIa cross-linking sites including the αC-αC connector region — before becoming covalently stabilized by Factor XIIIa³³ Factor XIIIa
Factor XIII is a transglutaminase activated by thrombin; it covalently cross-links adjacent fibrin alpha and gamma chains, converting the gel into a mechanically resistant clot.

Standeven et al. demonstrated⁴⁴ Standeven et al. demonstrated
Standeven KF et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation, 2003 that the Ala312 variant falls within the region of the alpha chain targeted by Factor XIIIa for alpha-alpha cross-linking. The substitution alters the geometry of this domain, enhancing the efficiency of Factor XIIIa-mediated cross-linking between adjacent alpha chains. The consequence is a fibrin network with a more compact architecture: denser fiber packing, reduced pore size, and — critically — greater resistance to fibrinolysis by plasmin. Clots formed from Ala312 fibrinogen are structurally stiffer and dissolve more slowly.

This mechanism explains the selectivity of the risk: pulmonary embolism, not deep vein thrombosis is the predominant association. A denser, plasmin-resistant clot is more likely to embolize intact before local thrombolysis can fragment it. DVT formation is determined more by flow conditions and early thrombin generation; the lysis-resistant clot phenotype becomes clinically relevant downstream, when the thrombus must be dissolved or risks breaking off.

The Evidence

The original clinical association was established by Carter et al. 2000⁵⁵ Carter et al. 2000
Carter AM et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood, 2000 in a study of 99 pulmonary embolism patients, 122 DVT patients, and 254 healthy controls. The Ala312 genotype frequency was 15% in PE patients versus 6% in controls (P=.02), while DVT patients showed no significant difference from controls. A significant genotype-by-genotype interaction was also found between Thr312Ala and the Factor XIII Val34Leu variant (rs5985, P=.01), consistent with their shared biology at the Factor XIIIa cross-linking interface.

An earlier landmark finding came from Carter et al. 1999⁶⁶ Carter et al. 1999
Carter AM et al. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation, 1999 in 519 acute ischemic stroke patients. Among the 101 patients with atrial fibrillation — a condition associated with intra-atrial thrombus formation — survival differed strikingly by genotype: TT carriers had 42% survival, TA heterozygotes 18%, and AA homozygotes 0%. The authors proposed that Ala312-containing fibrinogen makes atrial thrombi more lysis-resistant and more susceptible to embolization, providing a coherent structural explanation for why clot structure — not just clot presence — determines embolic outcome.

A 2025 meta-analysis by Cheng et al.⁷⁷ meta-analysis by Cheng et al.
Cheng H et al. Association of Fibrinogen Aα Thr312Ala polymorphism with VTE and chronic thromboembolic pulmonary hypertension: a meta-analysis. Clin Appl Thromb Hemost, 2025 synthesized 11 studies covering 3,856 individuals with VTE events and 761 with chronic thromboembolic pulmonary hypertension⁸⁸ chronic thromboembolic pulmonary hypertension
CTEPH arises when pulmonary emboli fail to fully resolve, leaving organized clot that progressively obstructs pulmonary arteries — the structural counterpart of the fibrinolysis-resistant clot phenotype that Ala312 fibrinogen produces. The Ala312 allele was consistently associated with elevated VTE and CTEPH risk across all genetic models in Caucasian and Asian populations. The CTEPH association is particularly striking: CTEPH is the long-term consequence of recurrent or incompletely lysed pulmonary emboli, exactly the pathological endpoint predicted by lysis-resistant fibrin clot structure.

The variant is not significantly associated with coronary artery disease in cohort data, consistent with its mechanism being fibrinolysis resistance rather than initial atherothrombotic plaque rupture.

Practical Implications

Carrying the Ala312 allele does not cause thrombosis on its own — the background risk requires permissive conditions: prolonged immobility, surgery, oral contraceptives, pregnancy, cancer, or a second thrombophilic variant such as Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963). What this variant does is shift the structural phenotype of fibrin clots toward greater lysis resistance, increasing the probability that a thrombus that forms will embolize or persist. Awareness of this genotype should heighten attention to VTE prevention during high-risk periods and prompt early investigation when symptoms of PE occur.

Women using combined oral contraceptives face a substantially amplified risk if they also carry Ala312: estrogens already raise fibrinogen levels and shift clot structure toward a prothrombotic phenotype; Ala312 compounds this by making the resulting clot harder to dissolve.

Interactions

Factor XIII Val34Leu (rs5985): The Carter 2000 paper identified a significant interaction (P=.01) between Thr312Ala and Factor XIII Val34Leu. These two variants affect opposite sides of the same biochemical event — Ala312 in the fibrinogen alpha chain substrate, and Leu34 in the Factor XIIIa enzyme — and their combined effect on clot structure is not simply additive. Leu34 increases Factor XIIIa activation rate; Ala312 alters the cross-linking geometry. Co-carriage may produce a distinctly abnormal clot phenotype.

FGB -455G>A (rs1800790): The Klajmon 2022 study (PMID 34783023) found that FGB rs1800790 A allele (reduced fibrinogen beta chain expression) affects fibrin clot permeability and lysis time in acute PE, while FGA rs6050 alone did not reach significance in that dataset. This suggests the two fibrinogen chain variants have partially independent and potentially interacting effects on clot structure.

Factor V Leiden (rs6025) and Prothrombin G20210A (rs1799963): These classic inherited thrombophilias act upstream (at the coagulation protease level) while Ala312 acts downstream (at the fibrin scaffold level). Co-inheritance of Ala312 with Factor V Leiden creates both increased thrombin generation and a structurally resistant clot — a compounded thrombophilic state warranting lower threshold for anticoagulation after a first VTE event.

The human leukocyte antigen (HLA) region on chromosome 6 is the single largest genetic risk factor for rheumatoid arthritis (RA), and within it the HLA-DRB1 gene dominates. rs660895 is a regulatory tag SNP that travels almost exclusively with the HLA-DRB1*04:01 allele¹¹ HLA-DRB1*04:01 allele
HLA alleles encode the antigen-binding groove of class II molecules; *04:01 is one of the alleles carrying the "shared epitope" motif at positions 70–74 of the beta chain. The G allele marks this high-risk haplotype; homozygosity for G roughly doubles the shared-epitope dose and substantially amplifies RA risk and severity.

The Mechanism

HLA-DRB1 encodes the beta chain of a class II MHC molecule that sits on the surface of antigen-presenting cells and presents peptide fragments to CD4+ T cells. The shared epitope is a five-amino-acid sequence (QKRAA, QRRAA, or RRRAA) in the peptide-binding groove²² peptide-binding groove
specifically at positions 70–74 of the DRβ1 hypervariable region-3. This motif is particularly efficient at binding and displaying citrullinated peptides — proteins where arginine residues have been chemically modified (citrullinated) by the enzyme PAD4. CD4+ T cells recognising these citrullinated epitopes drive B cells to produce anti-citrullinated protein antibodies (ACPA/anti-CCP), the hallmark autoantibody of seropositive RA. The SE alleles explain roughly 18% of the genetic variance in ACPA-positive RA — by far the largest single-locus contribution of any common variant.

The Evidence

Disease susceptibility. The SE gene-dose effect on ACPA-positive RA susceptibility is one of the most replicated findings in autoimmune genetics. Barra et al. 2010³³ Barra et al. 2010
HLA-DRB1 Genotypes and the Risk of Developing ACPA-Positive RA. PLOS One 2013; genotypic ORs ranging from 0.19 to 28 across DRB1 alleles in 857 cases showed a gradient from strongly protective to highly susceptible alleles, with *04:01 conferring among the highest ORs.

Joint damage progression. rs660895 does more than predict susceptibility — it predicts how fast joints will erode. In the CARDERA trial cohort (524 early RA patients followed for 2 years), Canhão et al. 2015⁴⁴ Canhão et al. 2015
Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis? J Rheumatol 2015 found that each G allele of rs660895 was associated with a 1.07-fold greater annual increase in Larsen radiographic score (p=0.0003). Critically, this association held only in ACPA-positive patients (β=1.08, p=0.011); no effect was seen in ACPA-negative patients (β=1.04, p=0.43). A subsequent meta-analysis of seven RA radiographic GWAS⁵⁵ meta-analysis of seven RA radiographic GWAS
Genetic associations with radiological damage in RA: meta-analysis of 2,775 cases. Arthritis Res Ther 2019 confirmed rs660895 as the most consistently replicated genetic predictor of joint damage.

Extra-articular disease. Turesson et al. 2004⁶⁶ Turesson et al. 2004
Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004 found that rs660895(G;G) homozygotes had an odds ratio of 6.2 (CI 1.01–37.9) for rheumatoid vasculitis, one of the most severe extra-articular manifestations of RA.

Treatment response. Yilmaz et al. 2024⁷⁷ Yilmaz et al. 2024
Association of HLA-DRB1 with treatment response to abatacept or TNF inhibitors in seropositive RA. Sci Rep 2024 found that SE-positive (G-allele) patients responded better to abatacept (a CTLA4-Ig that blocks T-cell co-stimulation) than to TNF inhibitors. This suggests rs660895 genotype can help rheumatologists choose between biologic classes in seropositive RA.

Practical Actions

Carrying one or two G alleles does not mean RA is inevitable — lifestyle and environmental factors (notably smoking, which dramatically amplifies SE risk) are co-required triggers. However, G carriers who are ACPA-positive have substantially higher odds of rapid radiographic progression and should pursue aggressive disease management early. ACPA testing and baseline hand/feet X-rays (or ultrasound/MRI) are the key monitoring tools. If RA does develop, rheumatologists should be aware that SE-positive patients may respond preferentially to abatacept over TNF inhibitors. Smoking cessation is uniquely important in G-allele carriers because gene-environment interaction with smoking multiplies RA risk superadditively.

Interactions

rs660895 acts in the same antigen-presentation pathway as rs2476601 (PTPN22 R620W), the second largest RA risk locus. When both are present (a common scenario given both are relatively frequent), RA risk is multiplicative rather than additive — each amplifies T-cell autoreactivity through distinct mechanisms (peptide presentation vs. T-cell receptor signalling). The interaction between SE alleles and rs2476601 has been confirmed in multiple large European cohorts.

The G allele also shows a protective association with Parkinson's disease (PD): in a meta-analysis of 44,451 individuals⁸⁸ meta-analysis of 44,451 individuals
Hamza et al. Mov Disord 2012, rs660895-G was associated with reduced PD risk (OR 0.86), suggesting HLA-DRB1*04:01 confers an immune-surveillance benefit against alpha-synuclein accumulation.

Deep inside your liver cells, tiny fat droplets accumulate when caloric intake, alcohol, or metabolic stress overwhelm the liver's processing capacity. Coating the surface of these fat droplets is a lipid droplet–associated enzyme called HSD17B13¹¹ HSD17B13
Hydroxysteroid 17-beta dehydrogenase 13, a member of the short-chain dehydrogenase/reductase enzyme family exclusively expressed in hepatocytes. In most people, this enzyme is fully active — and paradoxically, its activity appears to drive inflammation, fibrosis, and liver disease progression. One of the most striking discoveries in liver genetics over the past decade is that losing HSD17B13 function is protective: a naturally occurring insertion variant that silences the enzyme is associated with dramatically reduced risk of nonalcoholic steatohepatitis (NASH), alcoholic liver disease, cirrhosis, and hepatocellular carcinoma.

The Mechanism

The rs72613567 variant consists of an adenine insertion (;A) immediately adjacent to the donor splice site²² donor splice site
The nucleotide sequence at the exon-intron boundary where the spliceosome cuts to remove the intron; disruption here causes aberrant or skipped splicing of intron 6 in HSD17B13. This insertion disrupts normal mRNA processing, producing an alternative transcript (termed isoform D) that is frameshifted and encodes a truncated, enzymatically inactive protein. The truncated protein is also unstable — HSD17B13 protein levels in liver biopsies decrease proportionally to the number of insertion alleles carried.

HSD17B13 normally functions as a retinol dehydrogenase and lipid droplet–associated oxidoreductase, and it appears to modulate hepatic lipogenesis and lipid droplet expansion. Its loss alters the liver's phospholipid composition and suppresses inflammation-related gene expression pathways. Whole-transcriptome profiling of carriers shows downregulation of 274 genes, predominantly in immune response and inflammatory pathways — explaining why the loss-of-function state protects against the inflammatory cascade that drives NASH and fibrosis.

Critically, the variant does not protect against simple steatosis³³ steatosis
Fat accumulation in liver cells without inflammation; the earliest stage of fatty liver disease. The protection is specific to the progression from steatosis to steatohepatitis (inflammation) and fibrosis — meaning the enzyme's activity is particularly harmful during the transition to aggressive liver disease.

The Evidence

The landmark study from Abul-Husn et al. (NEJM 2018) analyzed 46,544 participants in the Geisinger Health System cohort: protective effect on alcoholic liver disease: 42% reduction in heterozygotes, 53% in homozygotes; on nonalcoholic liver disease: 17% and 30% reduction; on alcoholic cirrhosis: 42% and 73% reduction⁴⁴ protective effect on alcoholic liver disease: 42% reduction in heterozygotes, 53% in homozygotes; on nonalcoholic liver disease: 17% and 30% reduction; on alcoholic cirrhosis: 42% and 73% reduction
Abul-Husn NS et al. N Engl J Med 2018;378:1096-1106. These associations were replicated in independent cohorts totaling over 37,000 additional participants.

At the histology level, Pirola et al. (2019) examined 356 biopsy-proven NAFLD patients and found that each insertion allele reduces the odds of NASH (OR 0.61), ballooning degeneration (OR 0.47), and lobular inflammation (OR 0.48) — all hallmarks of progressive liver disease: Pirola CJ et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with NAFLD. J Lipid Res, 2019⁵⁵ Pirola CJ et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with NAFLD. J Lipid Res, 2019.

A 2020 meta-analysis pooling over 564,000 participants confirmed protection across all liver disease categories: pooled OR 0.73 for any liver disease, 0.81 for cirrhosis, 0.64 for hepatocellular carcinoma⁶⁶ pooled OR 0.73 for any liver disease, 0.81 for cirrhosis, 0.64 for hepatocellular carcinoma
Wang P et al. HSD17B13 rs72613567 protects against liver diseases and histological progression of NAFLD: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci, 2020.

In alcoholic liver disease specifically, a multicenter study of 3,315 European patients found that TA carriers have significantly lower HCC risk (OR 0.73 in ALD patients, and OR 0.64 for HCC development among those with ALD): Yang J, Nault JC et al. Hepatology 2019;71:1099-1108⁷⁷ Yang J, Nault JC et al. Hepatology 2019;71:1099-1108.

The protective effect also modifies the impact of the major liver-risk variant PNPLA3 rs738409⁸⁸ PNPLA3 rs738409
The strongest common genetic risk factor for NAFLD and alcoholic liver disease — an I148M missense variant in adiponutrin/patatin-like phospholipase domain-containing protein 3: the HSD17B13 TA allele substantially attenuates the liver injury associated with the PNPLA3 G (risk) allele, demonstrating that these two variants interact within the same lipid droplet biology pathway.

One important nuance: in patients who have already progressed to portal hypertension and advanced cirrhosis, the protective effect appears attenuated — the variant protects against developing severe liver disease more than it improves outcomes once severe disease is established.

Practical Implications

For carriers of one or two insertion alleles, the evidence supports that your liver has a meaningful biological buffer against alcohol-induced inflammation and metabolic liver disease progression. However, this protection is not absolute — it operates on a spectrum and can be overwhelmed by sufficient stressor load (heavy alcohol use, severe obesity, or co-inherited liver-risk variants like PNPLA3 GG).

For non-carriers (DD genotype), the absence of this protection means that alcohol, metabolic syndrome risk factors, and other liver stressors carry a higher baseline risk for inflammatory liver disease progression. Periodic liver function monitoring (ALT/AST, GGT) and abdominal imaging is particularly valuable for informing decisions about alcohol consumption and metabolic management.

Interactions

The most important genetic interaction is with PNPLA3 rs738409 (I148M): the GG high-risk genotype at PNPLA3 markedly amplifies liver disease risk, but HSD17B13 TA carriers show attenuated ALT levels and less severe histology even when carrying PNPLA3 risk alleles. The ALT-lowering benefit of HSD17B13 TA is greatest among individuals with three or four steatogenic alleles across PNPLA3 and TM6SF2 (rs58542926).

TM6SF2 rs58542926 (E167K) impairs hepatic VLDL secretion and elevates liver triglycerides; like PNPLA3, its risk effect operates in the same lipid droplet biology axis where HSD17B13 exerts protection, making these three variants key components of any comprehensive liver genetic risk assessment.

Circulating vitamin D travels through the bloodstream almost entirely in a carrier-bound form — roughly 85-90% of the 25-hydroxyvitamin D 25(OH)D¹¹ 25(OH)D
The major circulating form of vitamin D measured by standard blood tests. It reflects total body vitamin D stores and is the number your doctor reports your doctor measures is hitched to vitamin D binding protein (VDBP)²² vitamin D binding protein (VDBP)
Also called group-specific component, or GC. A 58-kDa glycoprotein produced in the liver that is the primary transporter of vitamin D metabolites in blood. VDBP concentration and binding affinity are the two largest determinants of total circulating 25(OH)D, encoded by the GC gene on chromosome 4. The GC locus is the single strongest genetic determinant of circulating 25(OH)D in genome-wide studies — dwarfing contributions from vitamin D synthesis, activation, and receptor genes.

rs842999 is one of several independent intronic variants at the GC locus that tag haplotypes influencing VDBP expression level or binding efficiency. Unlike the missense variants rs7041 (Asp432Glu) and rs4588 (Thr436Lys), which define the classical Gc1f, Gc1s, and Gc2 protein isoforms, rs842999 does not change the amino acid sequence. Instead, it marks a haplotype block associated with altered gene expression or alternative splicing — the exact regulatory mechanism has not been characterized at a molecular level. In Danish family cohorts, rs842999 and rs4588 were the two GC variants most strongly driving the gene-level association with serum 25(OH)D, suggesting the two carry partially independent information about VDBP function.

The Mechanism

rs842999 sits in an intron of the GC gene on the minus strand at GRCh38 chr4:71745973. The G allele is the reference and the population-major allele in most ancestries; the C allele is the minor allele and functions as the risk allele associated with lower 25(OH)D. Because GC encodes VDBP — the protein that determines how much total vitamin D circulates in blood — variants that reduce VDBP expression or binding affinity translate directly into lower measured 25(OH)D on standard blood tests, even when vitamin D intake or sun exposure is the same as someone without the variant.

The C allele is common in European populations (~45% allele frequency) but is effectively absent in African populations (<0.5%) and very rare in East Asian populations. This population distribution mirrors the broader pattern at the GC locus, where C-allele haplotypes at intronic tag variants (including rs842999 and rs2282679) are markedly enriched in European ancestry groups.

The Evidence

The strongest evidence comes from a series of Danish family studies examining genetic predictors of vitamin D status. In the PLoS One 2014 study by Nissen et al.³³ Nissen et al.
Nissen J et al. Common variants in CYP2R1 and GC genes predict vitamin D concentrations in healthy Danish children and adults. PLoS One, 2014 (758 participants from 201 families), rs842999 and rs4588 were specifically identified as the GC variants most responsible for the gene-level 25(OH)D association, with a dose-dependent relationship: carriers of two G-alleles had higher 25(OH)D than one-G carriers, who had higher levels than zero-G carriers.

A companion study in the same cohort, Nissen et al. Genes & Nutrition 2014⁴⁴ Nissen et al. Genes & Nutrition 2014
Nissen J et al. Real-life use of vitamin D3-fortified bread and milk during a winter season: the effects of CYP2R1 and GC genes on 25-hydroxyvitamin D concentrations in Danish families, the VitmaD study. Genes Nutr, 2014, built a 4-SNP genetic risk score from rs10741657 (CYP2R1), rs10766197 (CYP2R1), rs4588 (GC), and rs842999 (GC), counting the C/A alleles at rs842999 as risk alleles. Across 0-8 risk alleles, there was a statistically significant negative linear trend with 25(OH)D concentrations (p < 0.0001), confirming that rs842999 contributes independently to genetic vitamin D risk.

The 2015 Am J Clin Nutr study by Nissen et al.⁵⁵ Nissen et al.
Nissen J et al. Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D3-fortified bread and milk during winter in Denmark. Am J Clin Nutr, 2015 extended these findings, showing that rs842999 and rs4588 in GC jointly predict 25(OH)D levels both after UVB irradiation (simulated sun exposure) and after 6 months of consuming vitamin D3-fortified foods, suggesting the genetic effect persists regardless of the vitamin D source (endogenous vs. dietary).

In a large Arizona cohort of 1,439 participants from two colorectal neoplasia trials, Hibler et al.⁶⁶ Hibler et al.
Hibler EA et al. Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev, 2012 reported that rs842999 was one of seven GC polymorphisms significantly associated with circulating 25(OH)D concentrations after adjustment (P < 0.01).

Practical Actions

Carriers of the C allele — particularly CC homozygotes — are likely to have lower baseline 25(OH)D for a given level of sun exposure and dietary intake. The practical response is the same as for other GC locus variants: check your 25(OH)D level, and if it is below the optimal range (75-100 nmol/L / 30-40 ng/mL), supplement with vitamin D3 at doses calibrated to your measured level. The key distinction from the population average is that CC carriers typically need higher maintenance doses to sustain the same 25(OH)D concentration as GG carriers. Studies using genetic risk scores that include rs842999 found that high-risk individuals show reduced responsiveness to vitamin D fortification, meaning the same supplement dose raises 25(OH)D less in CC carriers than in GG carriers.

Interactions

rs842999 is in partial linkage disequilibrium with rs2282679 (the strongest GWAS signal at the GC locus, r² varies by population) and with rs4588 (the Thr436Lys missense variant defining the Gc2 isoform). The three variants are not fully redundant — Nissen et al. showed rs842999 and rs4588 were independently selected as the top GC predictors, suggesting they tag distinct aspects of GC haplotype variation. A full vitamin D genetic risk assessment ideally includes rs842999 alongside rs4588 or rs2282679 and rs7041.

GC variants interact with CYP2R1 (rs10741657, the major vitamin D 25-hydroxylase SNP) in a way that compounds risk: individuals with risk alleles at both the synthesis step (CYP2R1) and the transport step (GC) have the lowest 25(OH)D and the least responsiveness to supplementation in the Danish studies. VDR variants (particularly rs2228570 / Fok1) modulate downstream vitamin D receptor signaling, so GC + VDR compound genotypes are worth assessing for people with persistent vitamin D insufficiency despite adequate supplementation.

Most women don't think of their eggs as requiring constant genomic maintenance, but oocytes suspended in meiotic arrest for decades are uniquely vulnerable to DNA damage accumulation. The protein encoded by INO80¹¹ INO80
Inositol-requiring 80; the ATPase catalytic subunit of the INO80 chromatin remodeling complex, which repositions nucleosomes at DNA lesion sites to expose broken DNA ends for repair machinery is one of the key guardians of this stability — and a variant in the gene's 3'UTR region has been linked to how long a woman's ovarian reserve remains functional.

The Mechanism

The INO80 complex is recruited to DNA double-strand breaks²² DNA double-strand breaks
DSBs; the most dangerous form of DNA damage, where both strands of the double helix are severed. If unrepaired, DSBs cause chromosome rearrangements or cell death within seconds of their formation. At the break site, INO80 evicts and repositions nucleosomes, unwrapping chromatin so that homologous recombination repair machinery — RAD51, BRCA1, BRCA2 — can access the damaged ends. Without adequate INO80, repair at DSBs stalls, γ-H2AX foci persist, and cells enter senescence³³ senescence
a permanent cell-cycle arrest; in follicle cells this translates directly to follicular atresia and loss of ovarian reserve.

INO80 has a second, equally critical function at telomeres. Cao et al. 2014⁴⁴ Cao et al. 2014
Cao T et al. The mINO80 chromatin remodeling complex is required for efficient telomere replication and maintenance of genome stability. Cell Res 24:1318–1331 showed that mouse cells lacking INO80 develop fragile telomeres — a signature of failed replication through telomeric repeats — leading to chromosome fusions and mitotic catastrophe. In oocytes, where telomere length correlates directly with developmental competence and embryo viability, this function is particularly consequential.

The rs9796 variant sits in the 3' untranslated region of INO80 (NM_017553.3:c.*974; GRCh38 chr15:40,979,249). This region is not translated into protein but controls mRNA stability and translation efficiency. The T allele on the plus strand (corresponding to the coding-strand A at c.*974) is associated with greater INO80 expression output — likely by disrupting an inhibitory microRNA binding site or stabilizing the mRNA 3' structure. The net effect is more INO80 protein, more efficient chromatin remodeling at damage sites, and slower oocyte attrition.

The Evidence

The primary evidence comes from the landmark 2021 GWAS of ovarian ageing. Ruth et al. 2021⁵⁵ Ruth et al. 2021
Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596:393–397 analysed age at natural menopause (ANM) in approximately 200,000 women of European ancestry. The INO80 locus reached genome-wide significance with the T allele at rs9796 associated with a beta of +0.155 years per allele — meaning TT homozygotes, on average, reach menopause approximately 0.31 years (around 4 months) later than AA homozygotes. This finding placed INO80 within the dominant biological theme of the 290-locus GWAS: DNA damage response genes — rather than hormonal or metabolic pathways — are the primary determinants of how quickly the ovarian reserve is depleted.

The DNA repair connection is biologically well-supported. Human cells with depleted INO80 show impaired survival after gamma-irradiation, delayed clearance of DSB markers, and premature entry into senescence — all consistent with a direct role in maintaining the genomic integrity that long-lived primary oocytes require.

Practical Actions

The most actionable intervention informed by this variant is NAD+ precursor supplementation. NAD+ is the essential cofactor for both PARP enzymes (which sense and signal DSBs) and sirtuin deacylases (which regulate chromatin compaction at damage sites). As women age, NAD+ levels in oocytes decline substantially. Bertoldo et al. 2020⁶⁶ Bertoldo et al. 2020
NAD+ Repletion Rescues Female Fertility during Reproductive Aging. Cell Rep 30:1670–1681 demonstrated in aged mice that NMN supplementation restored NAD+ levels in oocytes, dramatically improved oocyte quality and fertilization rates, and reversed reproductive ageing markers — effects mediated partly through SIRT2 activation and improved chromosomal cohesion maintenance.

For women planning delayed conception or undergoing IVF, this translates to a genotype-informed rationale for NMN or NR supplementation, particularly in carriers of the AA genotype who lack the T allele's protective influence on INO80 expression.

Interactions

The INO80 pathway intersects with NAD+ metabolism at multiple points: PARP1 (activated by DSBs, rapidly consumes NAD+) competes directly with sirtuins for the same NAD+ pool. In conditions of high DNA damage load — chronic oxidative stress, ageing, or reduced INO80-mediated repair efficiency — PARP activation can deplete NAD+ to levels that impair sirtuin function, creating a compounding cycle of genome instability. Variants in BRCA1 (rs1799966), BRCA2 (rs80359550), and other homologous recombination genes would interact additively with reduced INO80 expression, since INO80 acts upstream of BRCA1/2 recruitment to DSBs. Carriers of additional HR pathway variants alongside the AA genotype at rs9796 represent a subgroup with the greatest need for proactive genomic maintenance support.

The R268K variant (rs1208) is often used as a tag SNP for NAT2 acetylator status because it is in strong linkage disequilibrium ¹¹ Linkage disequilibrium means nearby genetic variants tend to be inherited together as a block rather than independently with rapid acetylator haplotypes. The A allele at this position tags the NAT2*4 rapid acetylator haplotype, which is the ancestral (wild-type) form of the enzyme with full activity.

Understanding Tag SNPs

A tag SNP is a genetic variant that can serve as a proxy for a larger haplotype block. ²² A haplotype block is a set of nearby variants on the same chromosome that are almost always inherited together In the case of rs1208, the A allele reliably indicates the presence of a rapid acetylator allele, while the G allele indicates a slow acetylator allele. This makes it useful for genotyping studies where testing all NAT2 variants is not practical. Notably, the G allele is very rare in East Asian populations (~4%) but common in Europeans (~43%) and Africans (~41%).

The Bigger Picture

Your NAT2 acetylator phenotype - rapid, intermediate, or slow - has practical consequences for both environmental exposures and medication responses. Slow acetylators clear certain carcinogens (particularly aromatic amines from cigarette smoke and heterocyclic amines from cooked meat) more slowly, allowing these compounds to interact with DNA for longer periods.

Metabolic Associations

Beyond detoxification, rs1208 was identified as the lead SNP in a genome-wide association study³³ genome-wide association study
Knowles JW et al. Identification and validation of NAT2 as an insulin sensitivity gene. J Clin Invest, 2015 linking NAT2 to insulin sensitivity. The slow acetylator genotype was associated with decreased insulin sensitivity independent of BMI, and nominally associated with increased fasting glucose, HbA1c, total and LDL cholesterol, triglycerides, and coronary artery disease risk.

Balancing Risks

Interestingly, slow acetylation is not universally bad. While slow acetylators have higher bladder cancer risk from smoking, rapid acetylators have higher colorectal cancer risk from well-done meat. This is because NAT2 can both activate and deactivate different carcinogens depending on the substrate. ⁴⁴ NAT2 can either detoxify a carcinogen or convert a pro-carcinogen into its active, DNA-damaging form The practical takeaway is universal: minimize exposure to both cigarette smoke and heavily charred meats regardless of your acetylator status.

Your airways rely on a rapid alarm system. When epithelial cells lining the bronchi are damaged by allergens, viruses, or pollutants, they release a signalling protein called IL-33 (interleukin-33)¹¹ IL-33 (interleukin-33)
An alarmin cytokine released from epithelial cell nuclei upon tissue damage; it binds the ST2 receptor on mast cells, ILC2s, eosinophils, and Th2 cells to initiate type-2 allergic inflammation — the core biology of asthma and hay fever. Several common IL33 variants are known to amplify this signal, raising asthma risk. The rs12551268 A allele appears to work in the opposite direction — a directional protective signal against childhood asthma observed in a Finnish birth cohort, though the effect has not yet reached statistical significance in the one published study.

The Mechanism

rs12551268 sits deep within intron 5 of IL33 on chromosome 9 (GRCh38 chr9:6,231,318), within an intron of the gene rather than in a coding region. The C allele is the common allele (~72% in Europeans), while the A allele is rarer (~28%). Intronic variants in this region of IL33 can influence gene expression by altering regulatory elements²² regulatory elements
DNA sequences within introns that can act as enhancers, silencers, or splice-efficiency regulators, shaping when and how much mRNA is produced from the gene or by modulating alternative splicing efficiency. The A allele may reduce IL33 mRNA output or alter the balance of full-length versus truncated isoforms — a mechanism consistent with the well-characterised protection conferred by the IL33 splice-LOF variant rs146597587³³ rs146597587
A rare splice-acceptor variant in IL33 that produces a truncated, ST2-blind IL-33 protein; carriers have 40% lower IL33 mRNA and are ~50% less likely to develop asthma (OR 0.47 in Smith et al. 2017). The precise functional mechanism of rs12551268 has not been established by experimental studies.

The Evidence

The primary evidence comes from a prospective Finnish birth cohort⁴⁴ prospective Finnish birth cohort
Teräsjärvi et al. 2024, APMIS; 146 children followed from birth to age 7 years; ST2 and IL-33 polymorphisms analysed alongside serum sST2 and IL-33 levels at 13 months and asthma diagnoses at 7 years (PMID 38566447). Among two ST2 SNPs (rs1041973, rs13408661) and three IL-33 SNPs (rs1342326, rs12551256, rs12551268) examined, children carrying variants of rs12551268 were less often diagnosed with asthma by age 7. However, the authors explicitly note that these differences were not statistically significant, a limitation expected in a cohort of 146 children.

The biological plausibility for protective IL33 intronic variants is strong. Smith et al. 2017 (PMID 28273074) demonstrated that the rare IL33 splice-LOF variant rs146597587-C reduces total IL33 mRNA by 40% and protects against asthma with OR 0.47 in over 6,400 cases. If rs12551268 influences IL33 expression even modestly in the same direction, the mechanism is identical: less IL-33 reaching mast cells, ILC2s, and eosinophils means a quieter type-2 alarm response to airway challenge.

Critically, the evidence remains at the emerging level. One birth cohort study of 146 children, with a non-significant trend, is insufficient to establish the A allele as protective with confidence. Larger GWAS and functional studies are needed to determine whether this variant acts through gene regulation, and if so, how large the effect is. The IL33 locus is densely studied in asthma genetics; this variant has not appeared in any published GWAS Catalog entry or large consortium GWAS.

Practical Actions

Because the evidence is not statistically significant and the study was small, no strong personalised interventions can be recommended based solely on rs12551268 genotype. The protective trend is consistent with a biologically coherent mechanism, but caution is warranted in interpreting an emerging signal.

For C-allele homozygotes (the common genotype, ~52% of Europeans), the full complement of IL-33 signalling is unmodified at this locus — the same IL-33 pathway considerations that apply to the general population apply here. Other IL33 and IL1RL1 variants in your profile (such as rs992969 for the major regulatory signal) provide better-established guidance for actionable steps.

Interactions

rs12551268 exists within the same IL33 locus as the well-characterised risk variant rs992969 and the rare protective LOF variant rs146597587. The ST2 receptor side of the same signalling axis is captured by rs13408661 and rs1041973 (IL1RL1). Together, these variants describe the full IL-33/ST2 pathway from ligand expression to receptor density. If rs992969 and rs12551268 are on different haplotypes, their effects on IL33 expression may partially offset or compound depending on the specific combination — though no published data model this interaction.

The insulin receptor (INSR) is the entry point for insulin signaling in every cell of the body. When insulin binds, it activates a receptor tyrosine kinase¹¹ A kinase is an enzyme that adds phosphate groups to target proteins, triggering a cascade of intracellular signals cascade that routes glucose into cells, stimulates glycogen synthesis, and suppresses glucose production by the liver. Disruption of INSR function — whether from rare mutations or common regulatory variants — is a central mechanism in insulin resistance and type 2 diabetes.

rs12610022 is an intronic variant located in intron 13 of INSR on chromosome 19p13.2. It is not a coding change and does not directly alter the insulin receptor protein sequence. Instead, as an intronic variant near a region known to harbor splicing regulatory elements, it may influence how the INSR gene is transcribed or spliced.

The Mechanism

The INSR gene produces two main protein isoforms, INSR-A and INSR-B, through alternative splicing²² Alternative splicing is a process where different exons of a gene are included or excluded from the final mRNA, producing distinct protein variants from a single gene of exon 11. INSR-B (with exon 11) is the dominant form in metabolic tissues — liver, muscle, and adipose — and mediates the classical glucose-lowering actions of insulin. INSR-A (without exon 11) has higher affinity for IGF-II and drives mitogenic rather than metabolic signaling. In type 2 diabetes, the INSR-A/INSR-B ratio is shifted toward the mitogenic isoform, reducing metabolic signal output per unit of insulin.

Intronic sequences flanking exon 11 contain splicing enhancers and silencers that control isoform balance. A variant in intron 13 — which lies downstream of the exon 11 splicing cassette — could plausibly influence secondary splicing events or INSR transcript stability, though the specific molecular effect of rs12610022 has not been experimentally confirmed. Its position in LD with functional exonic variants in the same gene (including rs2229431 in exon 13) means it may also act as a tag SNP for those nearby functional changes.

The Evidence

A sequencing study by Melkersson 2018³³ Melkersson 2018
Melkersson K. Sequencing of the insulin receptor (INSR) gene reveals association between gene variants in exon and intron 13 and schizoaffective disorder. Neuro Endocrinol Lett, 2018 conducted whole-gene INSR sequencing in 105 patients with schizophrenia or schizoaffective disorder and 60 healthy controls. The study identified rs12610022 (intron 13) as showing tendencies toward significant differences in allele and genotype distribution specifically in schizoaffective disorder patients versus controls — a finding consistent with the emerging hypothesis that impaired insulin receptor signaling in the brain contributes to psychotic illness. The study is small (165 total participants) and rs12610022 did not reach conventional GWAS thresholds independently; replication in larger cohorts is needed.

Separately, Kaminska et al. 2014⁴⁴ Kaminska et al. 2014
Kaminska D et al. Adipose tissue INSR splicing in humans associates with fasting insulin level and is regulated by weight loss. Diabetologia, 2014 demonstrated that adipose tissue expression of INSR-B correlates negatively with fasting insulin levels (p = 3×10⁻²²) across three independent cohorts, and weight loss — via bariatric surgery or caloric restriction — restores INSR-B expression. This establishes the biological plausibility that intronic regulatory variants influencing INSR isoform balance would have measurable metabolic consequences.

The G allele of rs12610022 is rare in Europeans (~6%) but substantially more common in East Asian populations (~58%), which may explain why metabolic associations have been difficult to detect in predominantly European study cohorts.

Practical Implications

For carriers of one or two G alleles, the evidence is too early for specific clinical guidance. The most actionable insight from INSR biology is that receptor sensitivity is modifiable: adipose INSR-B expression responds robustly to weight loss, meaning that reducing adipose mass directly upregulates the metabolically favorable isoform regardless of underlying genotype. Monitoring fasting insulin (rather than glucose alone) provides an earlier window into insulin signaling competence.

Interactions

rs12610022 lies in the same gene as several better-studied INSR variants. The rs2229431 exon 13 variant was the primary finding in the same Melkersson 2018 study, suggesting the intron 13 and exon 13 variants may tag a common haplotype. The widely studied rs1799817 (His1085His, exon 17) and rs2059807 have established associations with PCOS and insulin resistance in multiple ethnic populations. If you carry risk alleles at multiple INSR positions, the combined effect on receptor function warrants closer metabolic monitoring.

Every neuron, including the dopamine-producing cells of the substantia nigra¹¹ substantia nigra
The midbrain region housing dopaminergic neurons whose iron stores are consistently reduced in restless legs syndrome even when blood iron is normal, depends on a steady supply of iron to sustain normal function. But iron cannot simply diffuse into the brain — it must cross specialized barriers, and the protein that controls its export from cells along this route is ferroportin²² ferroportin
The sole known mammalian iron exporter, encoded by SLC40A1 on chromosome 2, expressed on enterocytes, macrophages, and critically the choroid plexus epithelial cells and ependymal cells lining the brain's ventricles. The rs12693542 variant sits approximately two kilobases upstream of the SLC40A1 gene in a regulatory region, where it influences how much ferroportin the cell produces. The G allele — a minority variant in most populations — is associated with increased susceptibility to restless legs syndrome³³ restless legs syndrome
Also called Willis-Ekbom disease; a neurological condition causing irresistible urges to move the legs, typically at rest and worst in the evening, affecting 5-10% of adults.

The Mechanism

Restless legs syndrome is not, as was long assumed, primarily a dopamine disorder. Post-mortem neuropathology⁴⁴ Post-mortem neuropathology
Connor JR et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003 consistently shows iron-deficient substantia nigra in RLS brains, but the cellular machinery looks normal: no dopaminergic degeneration, no Lewy bodies. The iron simply isn't getting in. The iron stores of [neuromelanin cells | Pigmented dopamine-producing neurons in the substantia nigra that normally accumulate large iron deposits through the lifespan] — which normally accumulate iron throughout life — are markedly depleted in RLS brains compared to age-matched controls.

The route iron takes into the brain is circuitous. Iron from the bloodstream enters [choroid plexus | A network of epithelial cells in the brain's ventricles that produces cerebrospinal fluid and acts as a selective iron gateway into the CNS] epithelial cells, crosses those cells, and is then exported via ferroportin into cerebrospinal fluid, which delivers iron to brain tissue. A second route crosses the blood-brain barrier microvasculature. Studies of RLS brains⁵⁵ Studies of RLS brains
Connor JR et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011 found paradoxically elevated ferroportin in the choroid plexus of RLS patients — a likely compensatory response to the iron-deficient brain environment — alongside reduced IRP1 activity, suggesting dysregulated cellular iron sensing.

Critically, laser capture microdissection⁶⁶ laser capture microdissection
Connor JR et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology, 2004 of individual neuromelanin cells from RLS substantia nigra found reduced ferroportin, reduced transferrin receptor, reduced H-ferritin, and reduced IRP1 protein — a signature of cellular iron starvation despite the compensatory upregulation at the choroid plexus. The upstream variant rs12693542 presumably modulates the baseline expression of SLC40A1, shifting the equilibrium of this already-fragile brain iron delivery system.

Hepcidin-ferroportin signaling⁷⁷ Hepcidin-ferroportin signaling
Clardy SL et al. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci, 2006 is also disrupted in RLS — pro-hepcidin was significantly decreased in CSF of early-onset RLS patients, while brain tissue showed elevated pro-hepcidin in the substantia nigra and putamen. This bidirectional hepcidin dysregulation compounds any genetically reduced ferroportin expression, creating a milieu in which the brain chronically under-delivers iron to precisely the neurons that need it.

The Evidence

The Schormair et al. 2024 meta-analysis⁸⁸ Schormair et al. 2024 meta-analysis
Schormair B et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nature Genetics, 2024 represents the definitive population genetics study of RLS to date — 116,647 cases and 1,546,466 controls of European ancestry, increasing the total genome-wide significant loci from 20 to 164. rs12693542 in the SLC40A1 regulatory region reached p=1.35×10⁻¹³, comfortably beyond genome-wide significance (p<5×10⁻⁸). This places it among the most robustly replicated common genetic risk factors for RLS, and directly implicates the ferroportin expression axis in disease pathogenesis.

The biological plausibility is high. Multiple independent lines of evidence converge: the neuropathological iron deficiency in RLS substantia nigra, the aberrant ferroportin expression at the blood-brain interface, the disrupted hepcidin-ferroportin signaling in RLS CSF and brain tissue, and now the GWAS signal upstream of the gene encoding ferroportin itself.

Practical Actions

The clinical implications follow directly from the pathophysiology. Iron therapy is an established first-line treatment for RLS when serum ferritin is low, and even in patients with "normal" peripheral iron. Current guidelines recommend iron supplementation when ferritin is below 75 µg/L, as clinical trials reviewed by Trenkwalder et al.⁹⁹ clinical trials reviewed by Trenkwalder et al.
Trenkwalder C et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 2018 demonstrate that intravenous iron preparations (ferric carboxymaltose, ferric gluconate) significantly reduce RLS symptom severity. The therapeutic target for brain iron delivery is a serum ferritin well above the lower limit of the normal reference range — typically 100-150 µg/L for optimal neurological iron availability.

Oral iron supplementation is also effective for milder cases. Iron bisglycinate is better tolerated and has higher bioavailability than ferrous sulfate. Ferritin should be monitored at 3-month intervals when supplementing to track response and avoid overcorrection.

Importantly, the brain iron deficit in RLS is not simply a mirror of peripheral iron status. Some RLS patients have normal serum ferritin yet still respond to iron therapy, suggesting that the genetic variants affecting iron transport at the blood-brain interface — including SLC40A1 regulatory variants — create a CNS-specific iron insufficiency that is only partially captured by serum ferritin.

Interactions

rs12693542 operates within the broader iron homeostasis network. Three key interaction partners are represented elsewhere in the GeneOps database:

HFE variants rs1800562 (C282Y) and rs1799945 (H63D) cause hereditary hemochromatosis by raising serum iron — paradoxically, some hemochromatosis patients can still have RLS if brain iron delivery is impaired despite elevated peripheral iron. The combination of HFE iron overload genotype with the SLC40A1 upstream risk allele (reduced ferroportin expression) creates opposing pressures on the systemic versus neurological iron axis.

TMPRSS6 rs855791 (Ala736Val) affects hepcidin suppression and iron absorption efficiency. Individuals carrying both the TMPRSS6 A allele (reduced iron absorption) and the SLC40A1 G allele (impaired brain iron delivery) face compounded disadvantage: less iron in the bloodstream to begin with, and less efficient delivery to the CNS. This compound exposure likely represents the highest-risk subgroup for RLS driven by iron insufficiency.